{
  "id": 12698783,
  "title": "Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound",
  "url": "https://urgent.news/2026/10/07/where-will-eli-lilly-stock-be-in-5-years-follow-the-pipeline-beyond",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-07T19:18:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/07/where-will-eli-lilly-stock-be-in-5-years-follow-th/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly's stock, currently valued at over a trillion dollars, achieved this milestone in 2025. The company's success is largely attributed to its weight loss drug Zepbound, which is a top-selling pharmaceutical in its class. However, the coming years may bring increased competition to the weight loss medicine market, causing investors to question whether Eli Lilly can continue to generate solid returns or risk undermining shareholder wealth. The answer to this question largely depends on the progress of Eli Lilly's pipeline. Zepbound currently leads the anti-obesity market due to its superior efficacy compared to its main competitor, Novo Nordisk's Wegovy. Clinical trials have shown that Zepbound results in a significant weight loss of 20.2% over 72 weeks, while Wegovy achieved 13.7%. Moreover, Zepbound has outperformed Novo Nordisk's upcoming medicine, CagriSema, in head-to-head trials conducted with patients who were overweight or obese. The pharmaceutical industry is seeing several promising Phase 3 assets, including Novo Nordisk's own development of zenagamtide.",
  "summary": "The company is far from a one-trick pony.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}